These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 33973194)

  • 81. Immune Computation and COVID-19 Mortality: A Rationale for IVIg.
    Cohen IR; Efroni S; Atlan H
    Crit Rev Immunol; 2020; 40(3):195-203. PubMed ID: 33389884
    [TBL] [Abstract][Full Text] [Related]  

  • 82. COVID-19: Imbalanced Immune Responses and Potential Immunotherapies.
    Xie B; Zhang J; Li Y; Yuan S; Shang Y
    Front Immunol; 2020; 11():607583. PubMed ID: 33584679
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Convalescent plasma, cytomegalovirus infection, and persistent leukopenia in COVID-19 recovery phase: What is the link?
    Shah M; Kakar A; Gogia A; Langer S
    J Postgrad Med; 2021; 67(2):100-102. PubMed ID: 33942774
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Emerging Lessons From COVID-19 for the US Clinical Research Enterprise.
    Angus DC; Gordon AC; Bauchner H
    JAMA; 2021 Mar; 325(12):1159-1161. PubMed ID: 33635309
    [No Abstract]   [Full Text] [Related]  

  • 85. Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients.
    Kwapisz D; Bogusławska J
    Biomed Pharmacother; 2023 Jul; 163():114851. PubMed ID: 37167723
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Reducing transmission of SARS-CoV-2 with intranasal prophylaxis.
    Boiardi F; Stebbing J
    EBioMedicine; 2021 Jan; 63():103170. PubMed ID: 33340994
    [No Abstract]   [Full Text] [Related]  

  • 87. Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature.
    Choi S; Hwang S; Kwon K
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578407
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases.
    Tharmalingam T; Han X; Wozniak A; Saward L
    Hum Vaccin Immunother; 2022 Apr; 18(2):1886560. PubMed ID: 34010089
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope.
    Kumar A; Dey AD; Behl T; Chadha S; Aggarwal V
    Int Immunopharmacol; 2021 Jan; 90():107156. PubMed ID: 33189613
    [TBL] [Abstract][Full Text] [Related]  

  • 90. COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19.
    Sapir T; Averch Z; Lerman B; Bodzin A; Fishman Y; Maitra R
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955740
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Treatment of a case of COVID-19 by intravenous immunoglobulin.
    Çolak M; Kalemci S; Sarıhan A
    J Glob Antimicrob Resist; 2021 Mar; 24():106-107. PubMed ID: 33359936
    [TBL] [Abstract][Full Text] [Related]  

  • 92. An overview of some potential immunotherapeutic options against COVID-19.
    Bayat M; Asemani Y; Mohammadi MR; Sanaei M; Namvarpour M; Eftekhari R
    Int Immunopharmacol; 2021 Jun; 95():107516. PubMed ID: 33765610
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Administration of intravenous immunoglobulin in the treatment of COVID-19: A review of available evidence.
    Moradimajd P; Samaee H; Sedigh-Maroufi S; Kourosh-Aami M; Mohsenzadagan M
    J Med Virol; 2021 May; 93(5):2675-2682. PubMed ID: 33314173
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Antibody-Based Immunotherapeutic Strategies for COVID-19.
    Hussen J; Kandeel M; Hemida MG; Al-Mubarak AIA
    Pathogens; 2020 Nov; 9(11):. PubMed ID: 33167401
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Promising Immunotherapies against COVID-19.
    Guo H; Zhou L; Ma Z; Tian Z; Zhou F
    Adv Ther (Weinh); 2021 Aug; 4(8):2100044. PubMed ID: 34179345
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Immune-Cell-Based Therapy for COVID-19: Current Status.
    Wang Y; Liang Q; Chen F; Zheng J; Chen Y; Chen Z; Li R; Li X
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005826
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Therapeutic Agents Rounding Up the Immunopathology of COVID-19.
    Li HP; He X; Zhang L; Li CX; Li SQ; Li QY
    Ther Clin Risk Manag; 2021; 17():657-668. PubMed ID: 34234442
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Harnessing immunity: Immunomodulatory therapies in COVID-19.
    Velikova T; Valkov H; Aleksandrova A; Peshevska-Sekulovska M; Sekulovski M; Shumnalieva R
    World J Virol; 2024 Jun; 13(2):92521. PubMed ID: 38984079
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Understanding the Evolving Pathophysiology of Coronavirus Disease 2019 and Adult Nursing Management.
    Luckner KM; Seckel MA
    Crit Care Nurs Clin North Am; 2024 Sep; 36(3):295-321. PubMed ID: 39069352
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.
    Kang CK; Choe PG; Park S; Kim TS; Seong MW; Kim NJ; Oh MD; Park WB; Kim YW
    J Med Virol; 2020 Nov; 92(11):2371-2373. PubMed ID: 32458425
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.